Malte Roerden
@RoerdenM
Followers
173
Following
540
Media
0
Statuses
83
Physician-scientist interested in cancer immunology and immunotherapy | Postdoc in the Spranger lab @kochinstitute @MIT
Cambridge, MA
Joined October 2019
Excited to share our review that’s now out in @SciImmunology. We describe how DC-T cell interactions in lymph nodes specify CD8+ T cell fates and sustain anti-tumour immune responses. @stefanispranger @kochinstitute |
science.org
DC–T cell interactions during priming influence CD8+ T cell fate, and DCs subsequently sustain T cell responses against cancer.
0
3
16
Meet the Author: Malte Roerden (@RoerdenM), a physician-scientist from @kochinstitute, is 1st author of “Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression,” recently published in #JITC! 1/6
1
4
6
Looking forward to the visit!
The Program in Immunology welcomes Dr. Stefani Spranger @stefanispranger from @MITBiology and @kochinstitute. Please join us for her seminar on Monday January 13!
0
1
10
How different immune evasion mechanisms interfere with immunoediting of evolving tumors - @RoerdenM
@stefanispranger @NatRevImmunol
https://t.co/43Lj5IGoB6
#Cancer #ImmuneOnc #IO #ImmunoOncology #Immunotherapy #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology
oncodaily.com
Malte Roerden: How different immune evasion mechanisms interfere with immunoediting of evolving tumors / cancer, cancer immune evasion, immunoediting,
0
2
3
Check out the recent #JITC Editor Pick from Malte Roerden et al, "Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression" https://t.co/nX6mz2okNt
0
2
6
Very excited to share our recent work now published in @NatRevImmunol! We reviewed how immune evasion mechanisms interfere with immunoediting to fosters intratumor heterogeneity (ITH) and discuss data on the role of ITH itself in blunting anti-tumor immunity. @stefanispranger
Cancer immune evasion, immunoediting and intratumour heterogeneity
0
1
4
Thank you @jitcancer for the nice summary of our latest project where we studied how different neoantigen expression patterns impact anti-tumor immunity 👇
Here’s a closer look at #JITC article: “Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression” by authors @RoerdenM @stefanispranger from @kochinstitute 1/11
0
0
0
A big thanks to @stefanispranger and all contributors to the project!
0
0
0
Our latest paper is now out in #JITC! Modeling different NeoAg architectures, we found that these define the immunogenicity of tumor branches and uncover how they mediate immune evasion. Our findings may inform target prioritization for cancer vaccines. See link below!
New #JITC article: Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression https://t.co/6wpiAZEsVT
@RoerdenM @kevlitchfield @stefanispranger #SITC24
2
0
2
Low doses of MHC-II-restricted neoantigen peptides induce cytotoxic Tr1 CD4 T cells that kill cDC1 and suppress cancer immunotherapy, which can be overcome by LILRB4 blockade, CD8-directed IL-2 mutein, or targeted loss of cDC2/monocytes @Nature
https://t.co/e6m5MGHqMZ
0
22
106
Ludwig @MIT's @StefaniSpranger chaired a session at #AACR2024 on the crosstalk between various myeloid cells & T cells in tumors & lymph nodes. She also shared her lab's findings on how dendritic cells shape cytotoxic T cell responses & are themselves influenced by other T cells.
2
11
42
Combining tumor-targeting antibodies with IL-2 mRNA induces rejection of MHC class I-deficient tumors otherwise resistant to immune-, chemo-, and radiotherapy @Cancer_Cell
https://t.co/GlSyJkiCWZ
0
3
13
🚨👇🏻A fantastically creative approach for solving the challenge of safely enhancing T cell potency for adoptive immunotherapy. Amazing work from @jaehyukchoimd and @KoleRoybal.
2
24
102
We are hiring at multiple levels to join our team https://t.co/9EWMujapKA
@MITdeptofBE @kochinstitute Apply below! Postdoc: https://t.co/s2pSMBbRmQ Lab Coordinator: https://t.co/7fG5vEXgbS Tech: https://t.co/gxq8lV709k Please repost! #immunoengineering #synbio #glycotime #newPI
0
89
186
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2: https://t.co/6WSnFxt9vC
@stefanispranger @MITBiology
#Immunology
1
6
13
“We may be close to a new revolution of cancer vaccines.” If you missed our Cancer Vaccines symposium this summer, we’ve got you covered. Video of the panel and presentations at the link. https://t.co/V0bY2CaDYO
news.mit.edu
At a pivotal moment in cancer vaccine research, the MIT Koch Institute Annual Symposium explored emerging successes and obstacles in the field in areas that include immunology, next-generation tools...
0
8
37
QS ranks MIT the world’s number 1 university for 2023-24. This is the 12th year in a row for MIT, the Institute also places first in 11 subject areas. https://t.co/Ud4V76fkua and https://t.co/izplwmZISK
#ThisisMIT
8
32
226
I had a great time at my first professional symposium today with the @kochinstitute. It was especially neat to see the lab I am working with this summer be represented by an excellent presentation from @RoerdenM.
0
4
13
KI postdoc Malte Roerden is pitching in for Stefani Spranger this afternoon, sharing his lab's work on exploring the relationships between strong and weak neoantigens in eliciting immune responses in clonal and subclonal tumors. #KIsymposium
0
4
11